OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
12
Results
Show all
Save search
Copy query
Show results for
Unknown
(12)
Release Date
2024
(4)
2016
(2)
2025
(1)
2023
(1)
2022
(1)
2021
(1)
2019
(1)
2017
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
A Causal Role of Genetically Elevated Circulating Interleukin-10 in the Development of Digestive Cancers: Evidence from Mendelian Randomization Analysis Based on 29,307 Subjects.
Not available
S-EPMC4998630
|
biostudies-literature
Cite
Role of HDAC9-FoxO1 Axis in the Transcriptional Program Associated with Hepatic Gluconeogenesis.
Not available
S-EPMC5522426
|
biostudies-literature
Cite
Dexmedetomidine modulates neuroinflammation and improves outcome via alpha2-adrenergic receptor signaling after rat spinal cord injury.
Not available
S-EPMC6883489
|
biostudies-literature
Cite
A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis.
Not available
S-EPMC8020785
|
biostudies-literature
Cite
Identification of scaffold proteins for improved endogenous engineering of extracellular vesicles.
Not available
S-EPMC10406850
|
biostudies-literature
Cite
Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse models.
Not available
S-EPMC9314316
|
biostudies-literature
Cite
Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles.
Not available
S-EPMC11558116
|
biostudies-literature
Cite
Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors.
Not available
S-EPMC12041237
|
biostudies-literature
Cite
ATF3 is a neuron-specific biomarker for spinal cord injury and ischaemic stroke.
Not available
S-EPMC11035380
|
biostudies-literature
Cite
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Not available
S-EPMC11090892
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets